Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15021221 | 0.99 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL15021768 | 0.97 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL4565894 | 0.91 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL4565399 | 0.88 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL4565822 | 0.87 | TRPV1 (0.53) | TRPV1 | |
| SCHEMBL15021413 | 0.86 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL15022298 | 0.86 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL15021714 | 0.86 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL15021626 | 0.86 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL15021683 | 0.85 | TRPV1 (0.67) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | claimed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | claimed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | claimed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2012778-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | Abbott Laboratories (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121299-A2 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.